Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis. The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often used to […]
synspira
Synspira raises $8m for inhaled pulmonary therapies
Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study. The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive […]